Nisa Investment Advisors LLC cut its position in shares of Haemonetics Corporation (NYSE:HAE – Free Report) by 33.6% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 793 shares of the medical instruments supplier’s stock after selling 402 shares during the period. Nisa Investment Advisors LLC’s holdings in Haemonetics were worth $50,000 at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Haemonetics by 10.7% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,460 shares of the medical instruments supplier’s stock valued at $973,000 after purchasing an additional 1,202 shares in the last quarter. HighTower Advisors LLC boosted its stake in Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock valued at $262,000 after buying an additional 244 shares in the last quarter. Swiss National Bank grew its position in Haemonetics by 1.2% in the fourth quarter. Swiss National Bank now owns 100,700 shares of the medical instruments supplier’s stock valued at $7,863,000 after acquiring an additional 1,200 shares during the period. Natixis Advisors LLC bought a new stake in Haemonetics in the fourth quarter valued at $1,194,000. Finally, Cibc World Markets Corp acquired a new position in Haemonetics during the fourth quarter worth $367,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts have recently commented on HAE shares. Needham & Company LLC reduced their target price on shares of Haemonetics from $104.00 to $84.00 and set a “buy” rating on the stock in a research note on Thursday, May 8th. Wall Street Zen cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Barrington Research reissued an “outperform” rating and issued a $95.00 target price on shares of Haemonetics in a report on Friday, July 11th. Robert W. Baird initiated coverage on Haemonetics in a report on Thursday, June 26th. They set an “outperform” rating and a $87.00 price target for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $100.00 price objective on shares of Haemonetics in a research report on Tuesday, May 20th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $97.30.
Haemonetics Trading Down 1.2%
HAE stock opened at $72.55 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.62 and a debt-to-equity ratio of 1.12. Haemonetics Corporation has a twelve month low of $55.30 and a twelve month high of $94.99. The company has a market cap of $3.49 billion, a P/E ratio of 21.92, a PEG ratio of 1.19 and a beta of 0.39. The business has a fifty day moving average of $71.63 and a 200-day moving average of $67.93.
Haemonetics (NYSE:HAE – Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a return on equity of 26.37% and a net margin of 12.32%. The firm had revenue of $330.60 million during the quarter, compared to analysts’ expectations of $329.38 million. During the same period in the previous year, the business posted $0.90 EPS. The company’s quarterly revenue was down 3.5% compared to the same quarter last year. As a group, equities research analysts expect that Haemonetics Corporation will post 4.55 EPS for the current year.
About Haemonetics
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
- Five stocks we like better than Haemonetics
- Why Are These Companies Considered Blue Chips?
- Why Pure Storage Is a Core Investment for the AI Era
- When to Sell a Stock for Profit or Loss
- 2025: A Pivotal Year for Smart Glasses As Meta Invests in Ray-Ban
- How to start investing in penny stocks
- Unity’s New Ad Solutions Drive Stock to 52-Week High
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Corporation (NYSE:HAE – Free Report).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.